High Affinity InhA Inhibitors with Activity against Drug-Resistant Strains of Mycobacterium tuberculosis
journal contributionposted on 10.02.2006, 00:00 by Todd J. Sullivan, James J. Truglio, Melissa E. Boyne, Polina Novichenok, Xujie Zhang, Christopher F. Stratton, Huei-Jiun Li, Tejinder Kaur, Amol Amin, Francis Johnson, Richard A. Slayden, Caroline Kisker, Peter J. Tonge
Novel chemotherapeutics for treating multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (MTB) are required to combat the spread of tuberculosis, a disease that kills more than 2 million people annually. Using structure-based drug design, we have developed a series of alkyl diphenyl ethers that are uncompetitive inhibitors of InhA, the enoyl reductase enzyme in the MTB fatty acid biosynthesis pathway. The most potent compound has a K′i value of 1 nM for InhA and MIC99 values of 2–3 µg mL−1 (6–10 µM) for both drug-sensitive and drug-resistant strains of MTB. Overexpression of InhA in MTB results in a 9–12-fold increase in MIC99, consistent with the belief that these compounds target InhA within the cell. In addition, transcriptional response studies reveal that the alkyl diphenyl ethers fail to upregulate a putative efflux pump and aromatic dioxygenase, detoxification mechanisms that are triggered by the lead compound triclosan. These diphenyl ether-based InhA inhibitors do not require activation by the mycobacterial KatG enzyme, thereby circumventing the normal mechanism of resistance to the front line drug isoniazid (INH) and thus accounting for their activity against INH-resistant strains of MTB.
Read the peer-reviewed publication
MTB resultsMIC 991 nMmycobacterial KatG enzymeINHMycobacterium tuberculosistranscriptional response studiesMycobacterium tuberculosis Novel chemotherapeuticsMDRcompound triclosandetoxification mechanismsacid biosynthesis pathwayMIC 99 valuesfront line drug isoniazidHigh Affinity InhA Inhibitorsstrainenoyl reductase enzymealkyl diphenyl etherscompounds target InhA